Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03047317 | A Pharmacokinetic Study of MABp1 in Healthy Volunteers | PHASE1 | COMPLETED | 6 | — | — | Feb 15, 2017 | Mar 31, 2017 | Feb 16, 2021 | 1 | United States |
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
| Arm | Type | Description |
|---|---|---|
| MABp1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MABp1 | BIOLOGICAL | Single dose of intravenous MABp1 |
Inclusion Criteria: 1. Age: ≥18 2. Adequate bone marrow function as defined as: * absolute neutrophil count (neutrophil and bands) of ≥ 1,500/mm3 (≥ 1.5 x 109/L) * platelet count \> 150,000/mm3 * hemoglobin of ≥ 10 g/dL 3. Adequate renal function, defined by serum creatinine ≤ 1.5 x lab U...